 Polycystic Kidney, Autosomal Dominant
"Polycystic Kidney, Autosomal Dominant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Kidney disorders with autosomal dominant inheritance and characterized by multiple CYSTS in both KIDNEYS with progressive deterioration of renal function.
| Descriptor ID |
D016891
|
| MeSH Number(s) |
C12.777.419.403.875.500 C13.351.968.419.403.875.500 C16.131.077.717.500 C16.320.798.500
|
| Concept/Terms |
Polycystic Kidney, Autosomal Dominant- Polycystic Kidney, Autosomal Dominant
- Kidney, Polycystic, Autosomal Dominant
- Polycystic Kidney Disease, Adult
- Adult Polycystic Kidney Disease
- Polycystic Kidney Disease, Autosomal Dominant
- Autosomal Dominant Polycystic Kidney
- ADPKD
Polycystic Kidney, Type 2 Autosomal Dominant Disease- Polycystic Kidney, Type 2 Autosomal Dominant Disease
- Polycystic Kidney Disease, Adult, Type II
- Polycystic Kidney Disease, Type 2
- Polycystic Kidney Disease, Adult Type 2
- Adult Polycystic Kidney Disease Type 2
- Polycystic Kidney Disease 2
|
Below are MeSH descriptors whose meaning is more general than "Polycystic Kidney, Autosomal Dominant".
- Diseases [C]
- Male Urogenital Diseases [C12]
- Urologic Diseases [C12.777]
- Kidney Diseases [C12.777.419]
- Kidney Diseases, Cystic [C12.777.419.403]
- Polycystic Kidney Diseases [C12.777.419.403.875]
- Polycystic Kidney, Autosomal Dominant [C12.777.419.403.875.500]
- Female Urogenital Diseases and Pregnancy Complications [C13]
- Female Urogenital Diseases [C13.351]
- Urologic Diseases [C13.351.968]
- Kidney Diseases [C13.351.968.419]
- Kidney Diseases, Cystic [C13.351.968.419.403]
- Polycystic Kidney Diseases [C13.351.968.419.403.875]
- Polycystic Kidney, Autosomal Dominant [C13.351.968.419.403.875.500]
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Congenital Abnormalities [C16.131]
- Abnormalities, Multiple [C16.131.077]
- Polycystic Kidney Diseases [C16.131.077.717]
- Polycystic Kidney, Autosomal Dominant [C16.131.077.717.500]
- Genetic Diseases, Inborn [C16.320]
- Polycystic Kidney Diseases [C16.320.798]
- Polycystic Kidney, Autosomal Dominant [C16.320.798.500]
Below are MeSH descriptors whose meaning is more specific than "Polycystic Kidney, Autosomal Dominant".
This graph shows the total number of publications written about "Polycystic Kidney, Autosomal Dominant" by people in this website by year, and whether "Polycystic Kidney, Autosomal Dominant" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 | | 2000 | 3 | 0 | 3 | | 2001 | 1 | 0 | 1 | | 2002 | 2 | 0 | 2 | | 2003 | 2 | 0 | 2 | | 2004 | 3 | 0 | 3 | | 2005 | 1 | 1 | 2 | | 2006 | 2 | 0 | 2 | | 2007 | 2 | 0 | 2 | | 2008 | 4 | 0 | 4 | | 2009 | 0 | 1 | 1 | | 2010 | 7 | 0 | 7 | | 2012 | 4 | 0 | 4 | | 2013 | 3 | 0 | 3 | | 2014 | 10 | 0 | 10 | | 2015 | 5 | 1 | 6 | | 2016 | 5 | 1 | 6 | | 2017 | 5 | 0 | 5 | | 2018 | 9 | 0 | 9 | | 2019 | 5 | 0 | 5 | | 2020 | 12 | 0 | 12 | | 2021 | 7 | 0 | 7 | | 2022 | 7 | 0 | 7 | | 2023 | 9 | 0 | 9 | | 2024 | 5 | 0 | 5 | | 2025 | 6 | 0 | 6 | | 2026 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Polycystic Kidney, Autosomal Dominant" by people in Profiles.
-
Dahl NK, August P, Besse W, Chebib FT, Chonchol M, Cowley BD, Goral S, Guay-Woodford LM, Gulati A, Hogan MC, Lakhia R, Miskulin D, Nowak KL, Rahbari-Oskoui F, Park M, Seliger S, Yu A, Watnick T. KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Am J Kidney Dis. 2026 Apr; 87(4):447-507.
-
Birznieks CL, Wang W, Steele C, You Z, Gitomer B, Chonchol M, Nowak KL. Overweight and Obesity Are Associated with Lower Renal Blood Flow in Autosomal Dominant Polycystic Kidney Disease. Kidney Blood Press Res. 2026; 51(1):218-224.
-
Müller RU, Guerrot D, Chonchol M, Schmitt R, Uchiyama K, Gansevoort RT, Cornec-Le Gall E. SGLT2 inhibition for patients with ADPKD - closing the evidence gap. Nephrol Dial Transplant. 2025 Nov 26; 40(12):2231-2238.
-
Gitomer BY, Ostrow A, Wang W, George D, Coleman E, Nowak KL, Cadnapaphornchai MA, Patel NU, Steele C, Jovanovich A, Klawitter J, Farmer B, You Z, Chonchol M. A randomized controlled trial evaluated the effect of pravastatin on kidney disease outcomes in adult patients with early-stage autosomal dominant polycystic kidney disease. Kidney Int. 2026 Feb; 109(2):390-397.
-
Karl R, Ashraf APK, Viola MF, Hopp K, Mass E, Wachten D. Renal tissue-resident macrophages promote cystogenesis in early polycystic kidney disease. J Cell Sci. 2025 Oct 15; 138(20).
-
Ibel A, Bhardwaj R, Yilmaz DE, Kong S, Wendlinger S, Cordero C, Papaioannou D, Papazian M, Schönauer R, Meng Q, Eckardt KU, Hassan F, Volpe I, Klämbt V, Halbritter J, Fedeles S, Krappitz M, Kaminski MM. In vivo base editing reduces liver cysts in autosomal dominant polycystic kidney disease. Mol Ther. 2025 Nov 05; 33(11):5373-5382.
-
Pioppini C, Bhardwaj R, Schönauer R, Halbritter J, Hassan F, Eckardt KU, Fedeles SV, Yilmaz DE, Krappitz M. Valosin-containing protein in ciliary morphology: a novel target in ADPKD. Am J Physiol Renal Physiol. 2025 Aug 01; 329(2):F300-F310.
-
Torres VE, Ahn C, Barten TRM, Brosnahan G, Cadnapaphornchai MA, Chapman AB, Cornec-Le Gall E, Drenth JPH, Gansevoort RT, Harris PC, Harris T, Horie S, Liebau MC, Liew M, Mallett AJ, Mei C, Mekahli D, Odland D, Ong ACM, Onuchic LF, Pei YP, Perrone RD, Rangan GK, Rayner B, Torra R, Balk EM, Gordon CE, Earley A, Mustafa RA, Devuyst O. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary. Kidney Int. 2025 Feb; 107(2):234-254.
-
Sedaka R, Lovelady C, Hallit E, Duyvestyn B, Shinde S, Moran-Reyna A, Lee G, Yamaguchi S, Maynard CL, Saigusa T. Intestinal barrier function declines during polycystic kidney disease progression. Am J Physiol Renal Physiol. 2025 Feb 01; 328(2):F218-F229.
-
Atwood D, He Z, Miyazaki M, Hailu F, Klawitter J, Edelstein CL. Early treatment with 2-deoxy-d-glucose reduces proliferative proteins in the kidney and slows cyst growth in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease (PKD). Cell Signal. 2024 11; 123:111351.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|